Looks at how well deucravacitinib works for plaque psoriasis in everyday care
Observes deucravacitinib's real-world effect in adults with moderate-to-severe plaque psoriasis.
Plain-language title generated from the registry record
Registry title: A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
Key facts
- Where
- Amiens, Angers, Argenteuil, Arras, Bordeaux, Chalon-sur-Saône, Clermont-Ferrand, Dijon, La Tronche, Le Mans, Le Puy-en-Velay, Lens, Marcq-en-Barœul, Montpellier, Nice, Nîmes, Niort, Paris, Périgueux, Roubaix, Rouen, Saint-Germain-en-Laye, Saint-Mandé, Saint-Maur-des-Fossés, Toulon, Toulouse, Vandœuvre-lès-Nancy, and Villeurbanne, FranceSee the 31 sites
Where in France
- CHU Amiens-Picardie - Site SudAmiens, FranceTaking people
- Cabinet Médical Elisabeth LionAngers, FranceTaking people
- CH Victor DupouyArgenteuil, FranceTaking people
- ArgenteuilArgenteuil, FranceNo longer taking part
- CH ArrasArras, FranceTaking people
- Cabinet DermatologieBordeaux, FranceTaking people
- Centre Hospitalier William Morey - HématologieChalon-sur-Saône, FranceTaking people
- Clermont-FerrandClermont-Ferrand, FranceNo longer taking part
- DijonDijon, FranceNot yet recruiting
- CHU DijonDijon, FranceTaking people
- CHU Grenoble Alps, Service de DermatologieLa Tronche, FranceTaking people
- Le MansLe Mans, FranceNot yet recruiting
- CH Emile RouxLe Puy-en-Velay, FranceTaking people
- Centre Hospitalier LensLens, FranceTaking people
- Centre de santé FilierisMarcq-en-Barœul, FranceTaking people
- Hôpital Saint EloiMontpellier, FranceTaking people
- Tagast 41Nice, FranceTaking people
- Hopital CaremeauNîmes, FranceTaking people
- Ch Georges RenonNiort, FranceTaking people
- Cabinet de dermatologieParis, FranceTaking people
- ParisParis, FranceNo longer taking part
- Hopital Privé franchevillePérigueux, FranceTaking people
- Centre hospitalier de RoubaixRoubaix, FranceTaking people
- RouenRouen, FranceNo longer taking part
- Saint-Germain-en-LayeSaint-Germain-en-Laye, FranceNot yet recruiting
- HIA BeginSaint-Mandé, FranceTaking people
- Centre DermatologiqueSaint-Maur-des-Fossés, FranceTaking people
- Hia Sainte AnneToulon, FranceTaking people
- Hopital LarreyToulouse, FranceTaking people
- Hôpitaux de BraboisVandœuvre-lès-Nancy, FranceTaking people
- Médipôle Hôpital MutualisteVilleurbanne, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06701513
- Record updated
- 18 May 2026
- Original description
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasisRead full original descriptionShow less
Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-world, Prospective, Observational Study of the Effectiveness of Deucravacitinib in Adults With Moderate-to-Severe Plaque Psoriasis in France
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
Inclusion: ≥18 years of age; Physician-reported diagnosis of moderate to severe plaque psoriasis; Be newly initiating deucravacitinib; Do not object to participate.
Exclusion: Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial; Currently participating in or planning to participate in an interventional clinical trial.